U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Substance Use Tools & Resources   

Read the Guide

This collection of tools and resources is for providers, staff, and patients who offer or use services to address substance use, and other interested stakeholders. This collection was originally established following an environmental scan on implementing medication-assisted treatment (MAT) for opioid use disorder (OUD) in rural primary care. (See PDFs of Volume 1 [PDF 0.69 MB] and Volume 2 [PDF 1.28 MB] of that scan). Items have been continuously added to this collection since then, and the collection has expanded to cover substance use more broadly, rather than just MAT for OUD.

Displaying 11 - 20 of 45

Harm Reduction as a Trauma-Informed Approach to Substance Use - A Guide for Primary Care Providers

This guide provides information and strategies to primary care providers on harm reduction as a trauma informed approach to treating individuals with substance use disorder.
Format
Guide
Audience
Medical Providers
Behavioral Health Providers
Source
National Association of County and City Health Officials (NACCHO)
Year
Resource Type
PDF
File Size
593 KB

Substance Use and Substance Use Disorders by Race and Ethnicity, 2015-2019

This brief assesses whether and how rates of substance use and substance use disorder among adults differ by race and ethnicity using five years of data, 2015-2019, from the National Survey on Drug Use and Health.
Format
Report/Paper/Issue Brief
Audience
Policymakers and Payers
Source
Assistance Secretary for Planning and Evaluation (ASPE) / U.S. Department of Health and Human Services Office of Minority Health (OMH)
Year
Resource Type
PDF
File Size
473 KB

The Clinical Practice Guideline on the Management of Stimulant Use Disorder

This guideline provide evidence-based strategies and standards of care for the treatment of stimulant use disorders, stimulant intoxication, and stimulant withdrawal, as well as secondary and tertiary prevention of harms associated with stimulant use.
Format
Guide
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
American Society of Addiction Medicine (ASAM) / American Academy of Addiction Psychiatry (AAAP)
Year
Resource Type
PDF
File Size
1.9 MB

A Practical Research Agenda for Treatment Development for Stimulant Use Disorder - Meeting Summary: May 2022

This document summarizes a discussion from a workshop where experts examined the evidence for candidate endpoints and study design strategies for clinical trials of stimulant use disorder treatments.
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Reagan-Udall Foundation for the FDA (Food and Drug Administration)
Year
Resource Type
PDF
File Size
674 KB

Food and Drug Administration Overdose Prevention Framework

The FDA Overdose Prevention Framework consists of four overarching priorities that align with the U.S. Department of Health & Human Services' Overdose Prevention Strategy to address the public health emergency as it continues to evolve.
Format
Toolkit
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Food and Drug Administration (FDA)
Year
Resource Type
PDF
File Size
146 KB

Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health (NSDUH)

Based on 2022 and earlier NSDUH data, this report contains findings on a wide variety of key substance use and mental health indicators in the United States.

Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Substance Abuse and Mental Health Services Administration (SAMHSA)
Year
Resource Type
PDF

Margolis-FDA Workshop: Identifying Key Competencies for Opioid Prescriber Education

This was a two-day virtual public workshop (which can now be re-watched) that focused on identifying gaps in existing opioid prescriber education offerings and core competencies that should be included in educational content for opioid prescribers and other healthcare providers, including prescriber education under a Risk Evaluation and Mitigation Strategy (REMS).
Format
Webinar/Video
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Policymakers and Payers
Source
Duke-Margolis Center for Health Policy / Food and Drug Administration (FDA)
Year
Resource Type
Video